Deep Intelligent Pharma (DIP) closed a $50 million Series D round led by CDH Baifu to expand its autonomous clinical trial automation platform and global commercialization network. The company describes its technology as decomposing clinical development into thousands of high‑precision “atomic agents” to simulate and optimize trial execution, claiming industrial‑grade accuracy and reduced regulatory friction in pilot work. DIP said the funds will accelerate iterative product development and commercialization of autonomous systems for sponsors and CROs.